NexGel manufactures electron beam cross-linked aqueous polymer hydrogels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics, serving customers through three primary business models: contract manufacturing of bulk hydrogels for third-party incorporation into finished products including wound dressings, drug delivery patches, and medical devices; direct consumer sales of branded skincare and beauty products; and custom white-label offerings for customers to resell under their own brands. The company's competitive advantage derives from proprietary electron beam cross-linking technology that eliminates harsh chemical agents, enabling precise control of gel characteristics such as thickness, water content, and moisture transmission rates. Revenue comes from bulk roll-stock sales to manufacturers, direct-to-consumer and retail sales, and development fees from custom products, while the company operates at a fraction of its production capacity from a Pennsylvania facility and competes in contract manufacturing against limited direct rivals, though consumer products and medical devices face competition from larger healthcare companies.